Department of Psychiatry, Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium.
Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium.
BMC Psychiatry. 2020 Sep 16;20(1):453. doi: 10.1186/s12888-020-02856-x.
Major depressive episode (MDE) is worldwide one of the most prevalent and disabling mental health conditions. In cases of persistent non-response to treatment, electroconvulsive therapy (ECT) is a safe and effective treatment strategy with high response rates. Unfortunately, longitudinal data show low sustained response rates with 6-month relapse rates as high as 50% using existing relapse prevention strategies. Cognitive side effects of ECT, even though transient, might trigger mechanisms that increase relapse in patients who initially responded to ECT. Among these side effects, reduced cognitive control is an important neurobiological driven vulnerability factor for depression. As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).
METHOD/DESIGN: Eighty-eight patients aged between 18 and 70 years with MDE who start CCT will be included in this randomized controlled trial (RCT). Following (partial) response to ECT treatment (at least a 25% reduction of clinical symptoms), patients will be randomly assigned to a computer based CCT or active placebo control. A first aim of this RCT is to assess the effects of CCT compared to an active placebo condition on depression symptomatology, cognitive complaints, and quality of life. Secondly, we will monitor patients every 2 weeks for a period of 6 months following CCT/active placebo, allowing the detection of potential relapse of depression. Thirdly, we will assess patient evaluation of the addition of cognitive remediation to ECT using qualitative interview methods (satisfaction, acceptability and appropriateness). Finally, in order to further advance our understanding of the mechanisms underlying effects of CCT, exploratory analyses will be conducted using video footage collected during the CCT/active control phase of the study.
Cognitive remediation will be performed following response to ECT, and an extensive follow-up period will be employed. Positive findings would not only benefit patients by decreasing relapse, but also by increasing acceptability of ECT, reducing the burden of cognitive side-effects.
The study is registered with ClinicalTrials.gov . Study ID: NCT04383509 Trial registration date: 12.05.2020.
重度抑郁发作(MDE)是全球最普遍和致残的精神健康状况之一。在持续治疗无反应的情况下,电抽搐治疗(ECT)是一种安全有效的治疗策略,其反应率很高。不幸的是,纵向数据显示,使用现有的复发预防策略,6 个月的复发率高达 50%,持续反应率较低。ECT 的认知副作用,即使是短暂的,也可能触发机制,增加那些最初对 ECT 有反应的患者的复发率。在这些副作用中,认知控制能力下降是抑郁的一个重要神经生物学驱动的脆弱性因素。因此,认知控制训练(CCT)作为一种非药物策略有望提高 ECT 的长期效果(即增加缓解率,降低抑郁复发率)。
方法/设计:本随机对照试验(RCT)将纳入 88 名年龄在 18 至 70 岁之间的 MDE 患者,他们在接受 CCT 之前已经对 ECT 治疗有了(部分)反应(临床症状至少减少 25%)。患者将被随机分配到基于计算机的 CCT 或主动安慰剂对照组。该 RCT 的主要目的之一是评估 CCT 与主动安慰剂条件相比对抑郁症状、认知主诉和生活质量的影响。其次,我们将在 CCT/主动安慰剂后每 2 周监测患者 6 个月,以检测抑郁复发的潜在风险。第三,我们将使用定性访谈方法评估患者对 ECT 中添加认知矫正的评价(满意度、可接受性和适宜性)。最后,为了进一步深入了解 CCT 效果的潜在机制,我们将在研究的 CCT/主动对照阶段收集视频片段进行探索性分析。
认知矫正将在 ECT 治疗反应后进行,并且将采用广泛的随访期。积极的发现不仅可以通过降低复发率使患者受益,还可以提高 ECT 的可接受性,减轻认知副作用的负担。
该研究在 ClinicalTrials.gov 注册。研究 ID:NCT04383509 研究注册日期:2020 年 5 月 12 日。